Press |

Enzalutamide in the AFFIRM trial

The post hoc exploratory analysis of the AFFIRM trial (objective: to explore differences in efficacy and safety outcomes between European and North American patients) demonstrated a consistent OS benefit for enzalutamide in men with mCRPC who had previously progressed on docetaxel in both NA- and EU-treated patients, although the median OS was higher in EU relative to NA patients. Efficacy benefits were consistent across end points, with a comparable safety profile in both regions. Read the BJUI-abstract.

© 2019, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer   |   log in